| Cell line name | T-REx-293 | ||
|---|---|---|---|
| Synonyms | T-REx 293; T-REx293; TRex-293; TREx293; T-REx-HEK293; T-REx HEK 293; HEK293-T-REx | ||
| Accession | CVCL_D585 | ||
| Resource Identification Initiative | To cite this cell line use: T-REx-293 (RRID:CVCL_D585) | ||
| Comments | Group: Vaccine production cell line. Part of: ENCODE project common cell types; tier 3. Biotechnology: Used for the production of the AstraZeneca SARS-CoV-2 (COVID-19) vaccine (Trade name: Vaxzevria; also known as ChAdOx1-SARS-COV-2 or AZD1222) (DrugBank; DB15656). In the context of the vaccine production, the tetR repressor blocks the expression of the SARS-CoV-2 spike protein gene during production of the recombinant adenoviral vector, thereby optimising vector production. Transfected with: UniProtKB; P04483; E.coli Tn10 tetR. Transformant: NCBI_TaxID; 28285; Adenovirus 5. Derived from sampling site: Fetal kidney. | ||
| Species of origin | Homo sapiens (Human)
(NCBI Taxonomy: 9606)
| ||
| Hierarchy | Parent: CVCL_0045 (HEK293) Children:
| ||
| Sex of cell | Female | ||
| Age at sampling | Fetus | ||
| Category | Transformed cell line | ||
| Web pages | https://www.thermofisher.com/order/catalog/product/R71007 https://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/t/cell-lines-detail-410.html http://genome.ucsc.edu/ENCODE/protocols/cell/human/T-REx-HEK293_Farnham_protocol.pdf https://www.ema.europa.eu/en/documents/assessment-report/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-public-assessment-report_en.pdf | ||
| Cross-references | |||
| Cell line databases/resources | CCRID; 3142C0001000000950 | ||
| Ontologies | BTO; BTO:0005238
CLO; CLO_0037238 | ||
| Other | Wikidata; Q54971367 | ||
| Entry history | |||
| Entry creation | 22-Oct-2012 | ||
| Last entry update | 20-May-2021 | ||
| Version number | 16 | ||